Loading company…
SciNeuro Pharmaceuticals develops drugs for central nervous system diseases.
SciNeuro Pharmaceuticals researches and develops central nervous system drugs, including programs for Parkinson's and Alzheimer's diseases. Established in 2020 and based in Rockville, US, it raised USD 53 million in Series B funding in December 2025, co-led by Lilly Asia Ventures and ARCH Venture Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in